These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 36909046)

  • 21. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis.
    Li HL; Lip GYH; Feng Q; Fei Y; Tse YK; Wu MZ; Ren QW; Tse HF; Cheung BY; Yiu KH
    Cardiovasc Diabetol; 2021 May; 20(1):100. PubMed ID: 33962654
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The cardiovascular outcomes, heart failure and kidney disease trials tell that the time to use Sodium Glucose Cotransporter 2 inhibitors is now.
    Johansen ME; Argyropoulos C
    Clin Cardiol; 2020 Dec; 43(12):1376-1387. PubMed ID: 33165977
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Update on the Cardiovascular Benefits of Sodium-Glucose Co-Transporter-2 Inhibitors: Mechanism of Action, Available Agents and Comprehensive Review of Literature.
    Abdelmasih R; Abdelmaseih R; Thakker R; Faluk M; Ali A; Alsamman MM; Hasan SM
    Cardiol Res; 2021 Aug; 12(4):210-218. PubMed ID: 34349861
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction.
    Liu B; Wang Y; Zhang Y; Yan B
    Curr Top Med Chem; 2019; 19(20):1818-1849. PubMed ID: 31456521
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data.
    Hallow KM; Greasley PJ; Helmlinger G; Chu L; Heerspink HJ; Boulton DW
    Am J Physiol Renal Physiol; 2018 Nov; 315(5):F1295-F1306. PubMed ID: 30019930
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
    Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Furtado RHM; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
    Circulation; 2019 Apr; 139(17):2022-2031. PubMed ID: 30786725
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Incident heart failure and myocardial infarction in sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitor users.
    Zhou J; Lee S; Leung KSK; Wai AKC; Liu T; Liu Y; Chang D; Wong WT; Wong ICK; Cheung BMY; Zhang Q; Tse G
    ESC Heart Fail; 2022 Apr; 9(2):1388-1399. PubMed ID: 35132823
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-World Prescription Patterns and Barriers Related to the Use of Sodium-Glucose Cotransporter 2 Inhibitors among Korean Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease.
    Baek JH; Yang YS; Ko SH; Han KD; Kim JH; Moon MK; Park JS; Lee BW; Oh TJ; Chon S; Choi JH; Hur KY
    Diabetes Metab J; 2022 Sep; 46(5):701-712. PubMed ID: 35654585
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sodium-glucose Co-transporter 2 Inhibitors: a New Path for Heart Failure Treatment.
    Oh J; Lee SH; Lee CJ; Kang SM
    Korean Circ J; 2021 May; 51(5):399-408. PubMed ID: 33975387
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Roles for SGLT2 Inhibitors in Cardiorenal Disease.
    Green JB; McCullough PA
    Cardiorenal Med; 2022; 12(3):81-93. PubMed ID: 35835083
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of receptor selectivity on benefits from SGLT2 inhibitors in patients with heart failure: a systematic review and head-to-head comparative efficacy network meta-analysis.
    Täger T; Frankenstein L; Atar D; Agewall S; Frey N; Grundtvig M; Clark AL; Cleland JGF; Fröhlich H
    Clin Res Cardiol; 2022 Apr; 111(4):428-439. PubMed ID: 34498169
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical potential relevance of metabolic properties of SGLT2 inhibitors in patients with heart failure.
    Galli M; D'Amario D; Sofia C; Vaccarella M; Crea F; Aspromonte N
    Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1273-1285. PubMed ID: 30472914
    [No Abstract]   [Full Text] [Related]  

  • 33. Crosstalk between Sodium-Glucose Cotransporter Inhibitors and Sodium-Hydrogen Exchanger 1 and 3 in Cardiometabolic Diseases.
    Al-Shamasi AA; Elkaffash R; Mohamed M; Rayan M; Al-Khater D; Gadeau AP; Ahmed R; Hasan A; Eldassouki H; Yalcin HC; Abdul-Ghani M; Mraiche F
    Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884494
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Role of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Heart Failure, Regardless of Diabetes Status: Focus on Cardiovascular Disease.
    Ferrari F; Martins VM; Scheffel RS; da Silveira AD; Motta MT; Moriguchi EH; Santos RD; Stein R
    Ann Pharmacother; 2021 Oct; 55(10):1267-1275. PubMed ID: 33401940
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardioprotection conferred by sodium-glucose cotransporter 2 inhibitors: a renal proximal tubule perspective.
    Silva Dos Santos D; Polidoro JZ; Borges-Júnior FA; Girardi ACC
    Am J Physiol Cell Physiol; 2020 Feb; 318(2):C328-C336. PubMed ID: 31721613
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature.
    Burke KR; Schumacher CA; Harpe SE
    Pharmacotherapy; 2017 Feb; 37(2):187-194. PubMed ID: 27931088
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Emerging concepts in heart failure management and treatment: focus on SGLT2 inhibitors in heart failure with preserved ejection fraction.
    De Lorenzi AB; Kaplinsky E; Zambrano MR; Chaume LT; Rosas JM
    Drugs Context; 2023; 12():. PubMed ID: 36660013
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of Inpatient Initiation of Sodium-Glucose Cotransporter-2 Inhibitors on Prescription Rates in Patients With Heart Failure With Reduced Ejection Fraction.
    Okoroike H; Patel S; Simone P; Lavelle R; Szwak JA
    Am J Cardiol; 2023 Jan; 186():150-155. PubMed ID: 36283884
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Benefits of SGLT2i for the Treatment of Heart Failure Irrespective of Diabetes Diagnosis: A State-of-the-Art Review.
    Delgado E; Jódar E; Mezquita-Raya P; Moreno-Pérez Ó
    Diabetes Ther; 2022 Jul; 13(Suppl 1):19-34. PubMed ID: 35704165
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Beneficial effects of sodium glucose cotransporter 2 inhibitors on left ventricular mass in patients with diabetes mellitus.
    Kosugi D; Inaba H; Kaido Y; Ito S; Hirobata T; Toyofuku M; Matsuoka T; Inoue G
    J Diabetes; 2021 Nov; 13(11):847-856. PubMed ID: 34231959
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.